Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 15, 2018 Category: Nuclear Medicine Source Type: research
Table of Contents & Barcode
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 15, 2018 Category: Nuclear Medicine Source Type: research
A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter
In drug development, biomarkers for cerebral applications have a lower success rate compared to cardiovascular drugs or tumor therapeutics. One reason is the missing blood brain barrier penetration, caused by the tracer's interaction with efflux transporters such as the P-gp (MDR1 or ABCB1). Aim of this study was the development of a reliable model to measure the interaction of radiotracers with the human efflux transporter P-gp in parallel to the radiolabeling process. LigandTracer ® Technology was used with the wildtype cell line MDCKII and the equivalent cell line overexpressing human P-gp (MDCKII-hMDR1). (Source: Nucl...
Source: Nuclear Medicine and Biology - February 15, 2018 Category: Nuclear Medicine Authors: Chrysoula Vraka, Monika Dumanic, Teresa Racz, Florian Pichler, Cecile Philippe, Theresa Balber, Eva-Maria Klebermass, Karl-Heinz Wagner, Marcus Hacker, Wolfgang Wadsak, Markus Mitterhauser Source Type: research
A new Method Measuring the Interaction of Radiotracers with the human P-glycoprotein (P-gp) Transporter
In drug development, biomarkers for cerebral applications have a lower success rate compared to cardiovascular drugs or tumor therapeutics. One reason is the missing blood brain barrier penetration, caused by the tracer's interaction with efflux transporters such as the P-gp (MDR1 or ABCB1). Aim of this study was the development of a reliable model to measure the interaction of radiotracers with the human efflux transporter P-gp in parallel to the radiolabeling process. LigandTracer ® Technology was used with the wildtype cell line MDCKII and the equivalent cell line overexpressing human P-gp (MDCKII-hMDR1). (Source: Nucl...
Source: Nuclear Medicine and Biology - February 15, 2018 Category: Nuclear Medicine Authors: Chrysoula Vraka, Monika Dumanic, Teresa Racz, Florian Pichler, Cecile Philippe, Theresa Balber, Eva-Maria Klebermass, Karl-Heinz Wagner, Marcus Hacker, Wolfgang Wadsak, Markus Mitterhauser Source Type: research
Alanine and glycine conjugates of (2S,4R)-4-[18F]fluoroglutamine for tumor imaging
Glutamine is an essential source of energy, metabolic substrates, and building block for supporting tumor proliferation. Previously, (2S,4R)-4-[18F]fluoroglutamine (4F-Gln) was reported as a glutamine-related metabolic imaging agent. To improve the in vivo kinetics of this radiotracer, two new dipeptides, [18F]Gly-(2S,4R)4-fluoroglutamine (Gly-4F-Gln) and [18F]Ala-(2S,4R)4-fluoroglutamine (Ala-4F-Gln) were investigated. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 13, 2018 Category: Nuclear Medicine Authors: Zhihao Zha, Karl Ploessl, Brian P. Lieberman, Limin Wang, Hank F. Kung Source Type: research
Alanine and glycine conjugates of [18F](2S,4R)4-fluoroglutamine for tumor imaging
Glutamine is an essential source of energy, metabolic substrates, and building block for supporting tumor proliferation. Previously, [18F](2S,4R)4-fluoroglutamine (4F –Gln) was reported as a glutamine-related metabolic imaging agent. To improve the in vivo kinetics of this radiotracer, two new dipeptides, [18F]Gly-(2S,4R)4-fluoroglutamine (Gly-4F-Gln) and [18F]Ala-(2S,4R)4-fluoroglutamine (Ala-4F-Gln) were investigated. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 13, 2018 Category: Nuclear Medicine Authors: Zhihao Zha, Karl Ploessl, Brian P. Lieberman, Limin Wang, Hank F. Kung Source Type: research
Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after 177Lu[Lu]-octreotate therapy
Patients with neuroendocrine tumors expressing somatostatin receptors are often treated with 177Lu[Lu]-octreotate. Despite being highly effective in animal models, 177Lu[Lu]-octreotate-based therapies in the clinical setting can be optimized further. The aims of the study were to identify and elucidate possible optimization venues for 177Lu[Lu]-octreotate tumor therapy by characterizing transcriptional responses in the GOT1 small intestine neuroendocrine tumor model in nude mice. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 6, 2018 Category: Nuclear Medicine Authors: Johan Spetz, Nils Rudqvist, Britta Langen, Toshima Z. Parris, Johanna Dalmo, Emil Sch üler, Bo Wängberg, Ola Nilsson, Khalil Helou, Eva Forssell-Aronsson Source Type: research
Novel pyridine-containing azacrownethers for the chelation of therapeutic bismuth radioisotopes: Complexation study, radiolabeling, serum stability and biodistribution
Nowadays alpha-emitting radionuclides are the most perspective for target alpha therapy and 213Bi (T1/2 = 46 min) is one of the intensively studied for purpose. Despite the predominant decay by β-emission (98%) and only 2% by α-emission for 213Bi the presence of pure α-emitting 213Po and β-emitting 209Tl and 209Pb among its short-lived daughter radionuclides leads to its high therapeutic ef ficacy. The latter has already been demonstrated upon treatment of glioma, glioblastoma [1,2], neuroendocrine tumors [3] and prostate cancer [4]. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 6, 2018 Category: Nuclear Medicine Authors: B.V. Egorova, E.V. Matazova, A.A. Mitrofanov, G.Yu. Aleshin, A.L. Trigub, A.D. Zubenko, O.A. Fedorova, Yu.V. Fedorov, S.N. Kalmykov Source Type: research
Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after 177Lu-octreotate therapy
Patients with neuroendocrine tumors expressing somatostatin receptors are often treated with 177Lu-octreotate. Despite being highly effective in animal models, 177Lu-octreotate-based therapies in the clinical setting can be optimized further. The aims of the study were to identify and elucidate possible optimization venues for 177Lu-octreotate tumor therapy by characterizing transcriptional responses in the GOT1 small intestine neuroendocrine tumor model in nude mice. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 6, 2018 Category: Nuclear Medicine Authors: Johan Spetz, Nils Rudqvist, Britta Langen, Toshima Z. Parris, Johanna Dalmo, Emil Sch üler, Bo Wängberg, Ola Nilsson, Khalil Helou, Eva Forssell-Aronsson Source Type: research
Novel pyridine-containing azacrown-ethers for the chelation of therapeutic bismuth radioisotopes: complexation study, radiolabeling, serum stability and biodistribution
Nowadays alpha-emitting radionuclides are the most perspective for target alpha therapy and 213Bi (T1/2=46 min) is one of the intensively studied for purpose. Despite the predominant decay by β-emission (98%) and only 2% by α-emission for 213Bi the presence of pure α-emitting 213Po and β-emitting 209Tl and 209Pb among its short-lived daughter radionuclides leads to its high therapeutic efficacy. The latter has already been demonstrated upon treatment of glioma, glioblastoma [1,2], ne uroendocrine tumors [3] and prostate cancer [4]. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 6, 2018 Category: Nuclear Medicine Authors: B.V. Egorova, E.V. Matazova, A.A. Mitrofanov, G.Yu. Aleshin, A.L. Trigub, A.D. Zubenko, O.A. Fedorova, Yu.V. Fedorov, S.N. Kalmykov Source Type: research
[18F]RPS-544: A PET tracer for imaging the chemokine receptor CXCR4
CXCR4 specific [18F]-labeled positron emission tomography (PET) imaging agents are needed which would enable general distribution of the radiotracer for clinical investigation. We sought to synthesize, radiolabel and evaluate [18F]RPS-544, a novel non-peptide CXCR4 antagonist as a CXCR4 specific probe. We compared [18F]RPS-544 with the previously published [18F]-3 ([18F]RPS-510 in this paper) in a bi-lateral tumor model of differential CXCR4 expression for its ability to selectively target CXCR4 expression. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 4, 2018 Category: Nuclear Medicine Authors: Alejandro Amor-Coarasa, James Kelly, Shashikanth Ponnala, Yogindra Vedvyas, Anastasia Nikolopoulou, Clarence Williams, Moonsoo M. Jin, J. David Warren, John W. Babich Source Type: research
18F –labeled estradiol derivative for targeting estrogen receptor-expressing breast cancer
A novel radiotracer 1 ‑(2‑(2‑(2‑[18F]fluoroethoxy)ethoxy)ethyl)‑1H‑1,2,3‑triazole‑estradiol ([18F]FETE) was successfully synthesized, characterized and evaluated in mice for estrogen receptor (ER)-positive breast cancer targeting with positron emission tomography (PET) imaging. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 2, 2018 Category: Nuclear Medicine Authors: Duo Xu, Rongqiang Zhuang, Linyi You, Zhide Guo, Xiangyu Wang, Chenyu Peng, Deliang Zhang, Pu Zhang, Hua Wu, Weimin Pan, Xianzhong Zhang Source Type: research
Small-scale production of 67Cu for a preclinical study via the 64Ni( α, p)67Cu channel
In this study, we propose an easy small-scale production of 67Cu using 64Ni target for a preclinical study. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 2, 2018 Category: Nuclear Medicine Authors: Tomoyuki Ohya, Kotaro Nagatsu, Hisashi Suzuki, Masami Fukada, Katsuyuki Minegishi, Masayuki Hanyu, Ming-Rong Zhang Source Type: research
18F –labeled estradiol derivative for targeting estrogen receptor-expressing breast cancer
A novel radiotracer 1-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethyl)-1H-1,2,3-triazole- estradiol ([18F]FETE) was successfully synthesized, characterized and evaluated in mice for estrogen receptor (ER)-positive breast cancer targeting with positron emission tomography (PET) imaging. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - February 2, 2018 Category: Nuclear Medicine Authors: Duo Xu, Rongqiang Zhuang, Linyi You, Zhide Guo, Xiangyu Wang, Chenyu Peng, Deliang Zhang, Pu Zhang, Hua Wu, Weimin Pan, Xianzhong Zhang Source Type: research
